ENTX
Price
$2.06
Change
-$0.10 (-4.63%)
Updated
Sep 5 closing price
Capitalization
94.07M
61 days until earnings call
STOK
Price
$20.68
Change
+$1.05 (+5.35%)
Updated
Sep 5 closing price
Capitalization
1.13B
66 days until earnings call
Interact to see
Advertisement

ENTX vs STOK

Header iconENTX vs STOK Comparison
Open Charts ENTX vs STOKBanner chart's image
Entera Bio
Price$2.06
Change-$0.10 (-4.63%)
Volume$210.79K
Capitalization94.07M
Stoke Therapeutics
Price$20.68
Change+$1.05 (+5.35%)
Volume$543.6K
Capitalization1.13B
ENTX vs STOK Comparison Chart in %
Loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTX vs. STOK commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a Hold and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ENTX: $2.06 vs. STOK: $20.68)
Brand notoriety: ENTX and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 134% vs. STOK: 64%
Market capitalization -- ENTX: $94.07M vs. STOK: $1.13B
ENTX [@Biotechnology] is valued at $94.07M. STOK’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 3 bullish TA indicator(s).

  • ENTX’s TA Score: 5 bullish, 4 bearish.
  • STOK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ENTX is a better buy in the short-term than STOK.

Price Growth

ENTX (@Biotechnology) experienced а +6.74% price change this week, while STOK (@Biotechnology) price change was +4.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ENTX is expected to report earnings on Nov 06, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.13B) has a higher market cap than ENTX($94.1M). STOK YTD gains are higher at: 87.489 vs. ENTX (-2.830). STOK has higher annual earnings (EBITDA): 42.3M vs. ENTX (-10.55M). STOK has more cash in the bank: 248M vs. ENTX (10.9M). ENTX has less debt than STOK: ENTX (203K) vs STOK (2.3M). STOK has higher revenues than ENTX: STOK (200M) vs ENTX (166K).
ENTXSTOKENTX / STOK
Capitalization94.1M1.13B8%
EBITDA-10.55M42.3M-25%
Gain YTD-2.83087.489-3%
P/E RatioN/A23.77-
Revenue166K200M0%
Total Cash10.9M248M4%
Total Debt203K2.3M9%
FUNDAMENTALS RATINGS
ENTX vs STOK: Fundamental Ratings
ENTX
STOK
OUTLOOK RATING
1..100
782
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9946
PRICE GROWTH RATING
1..100
4935
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (60) in the null industry is in the same range as ENTX (73) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

ENTX's Profit vs Risk Rating (93) in the Pharmaceuticals Major industry is in the same range as STOK (100) in the null industry. This means that ENTX’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for ENTX (99) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than ENTX’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as ENTX (49) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

STOK's P/E Growth Rating (9) in the null industry is significantly better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew significantly faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXSTOK
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 17 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PWGAX20.220.13
+0.65%
PACE International Equity A
LMMRX31.21N/A
N/A
ClearBridge Dividend Strategy R
DOPIX34.02N/A
N/A
BNY Mellon Opportunistic Small Cap I
LADTX31.93N/A
N/A
Lord Abbett Developing Growth R5
CTAGX16.51N/A
N/A
Calamos Timpani SMID Growth A

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and STOK have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and STOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-4.63%
STOK - ENTX
32%
Poorly correlated
+5.35%
XENE - ENTX
31%
Poorly correlated
+1.48%
DNLI - ENTX
31%
Poorly correlated
+4.33%
IMNM - ENTX
30%
Poorly correlated
+7.35%
ORKA - ENTX
30%
Poorly correlated
+9.22%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+5.35%
IDYA - STOK
50%
Loosely correlated
+5.15%
QTTB - STOK
49%
Loosely correlated
+0.60%
SYRE - STOK
47%
Loosely correlated
+0.06%
IMNM - STOK
47%
Loosely correlated
+7.35%
DNLI - STOK
46%
Loosely correlated
+4.33%
More